Practice Economics

Supreme Court won’t hear IPAB challenge


 

References

The Supreme Court has declined to hear a case challenging the Independent Payment Advisory Board.

This leaves in place a ruling from the 9th U.S. Circuit Court of appeals, which dismissed the lawsuit Coons v. Lew, on the grounds that the plaintiffs failed to show harm from the provision of the Affordable Care Act that created the IPAB.

©trekandshoot/thinkstockphotos.com

The 15-member panel, created under the ACA to help control health care costs, is charged with identifying cuts to Medicare when the program’s spending exceeds gross domestic product plus 1%. Current slowing growth in Medicare spending had meant that the IPAB provision has not be triggered, and so far no members have been named to the panel.

Attorneys representing the plaintiff said they remain ready to refile their case if and when the IPAB is ever activated.

“This case is not dead; we’re simply in a holding pattern,” Christina Sandefur, senior attorney at the Goldwater Institute, said in a statement.

Congress also continues to look at the IPAB. In March, Rep. Phil Roe (R-Tenn.) reintroduced legislation to repeal the panel.

gtwachtman@frontlinemedcom.com

Recommended Reading

Value-based payment: Time to start getting ready
MDedge Hematology and Oncology
New bill consolidates SGR fix, CHIP reauthorization
MDedge Hematology and Oncology
Future physician shortages could be smaller than originally forecast
MDedge Hematology and Oncology
Value-based medicine gets boost from launch of information-sharing network
MDedge Hematology and Oncology
Medicare advisers: Cancer prognostic tests not ready for prime time
MDedge Hematology and Oncology
CMS: Stage 3 meaningful use by 2018
MDedge Hematology and Oncology
House votes to repeal SGR, reauthorize CHIP
MDedge Hematology and Oncology
Doctors hail House vote to repeal, replace SGR
MDedge Hematology and Oncology
Senate recesses without addressing SGR repeal bill
MDedge Hematology and Oncology
Commonwealth Fund: ACA’s medical loss ratio rule saves $5 billion
MDedge Hematology and Oncology